Author

S. Massey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Organism:virus· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

T. Brasel· 3 shared L. Wang· 2 shared R. M. Rubsamen· 2 shared R. T. Carback· 2 shared S. Burkholz· 2 shared T. Hodge· 2 shared A. D. T. Barrett· 1 shared A. D. Washburne· 1 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

T. Brasel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Statistical challenges for inferring multiple SARS-CoV-2 spillovers with early outbreak phylodynamics

A. D. Washburne, A. Jones, D. Zhang, Y. Deigin, S. Quay, S. Massey

This paper challenges claims of multiple SARS-CoV-2 spillovers by showing methodological flaws in genome analysis and phylodynamic modeling.

bioRxiv · Oct 10, 2022 · PreprintEvolutionary Biology

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim, S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J. D. Boyd-Kirkup, S. Guan, D. Thakkar, , B. J. Hanson

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

bioRxiv · Oct 26, 2020Microbiology

Anti-IL-6 versus Anti-IL-6R BlockingAntibodies to Treat Acute Ebola Infection inBALB/c Mice: Potential Implications forTreating Cytokine Release Syndrome

R. M. Rubsamen, S. Burkholz, S. Massey, T. Brasel, T. Hodge, L. Wang, C. Herst, R. T. Carback, P. Harris

This study shows that early IL-6 neutralization with an anti-IL-6 mAb improves outcomes in Ebola-infected mice, suggesting potential benefits for treating cytokine release syndrome.

bioRxiv · Jun 20, 2020Immunology

An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

C. V. Herst, S. Burkholz, J. Sidney, A. Sette, P. E. Harris, S. Massey, T. Brasel, E. Cunha-Neto, D. S. Rosa, W. C. H. Chao, R. T. Carback, T. Hodge, L. Wang, S. Ciotlos, P. Lloyd, R. M. Rubsamen

The paper identifies a conserved Ebola Zaire epitope that provides protection in mice and suggests its potential application in COVID-19 vaccine design.

bioRxiv · Feb 25, 2020Immunology